AI in Clinical Development is at the core of Parexel’s approach to accelerating first-time quality and milestone delivery through our strategic operating model, Parexel Precision Pathway. We’re committed to the development of innovative, high-value use cases for AI in clinical trials. AI empowers our people at critical decision points and our AI investments prioritize process optimizations that:
- Simplify complex tasks to accelerate timelines
- Apply insights with agility to enable better decision-making
- Enhance data handling to drive first time quality through content generation and workflow automation
Parexel has implemented AI and other advanced technologies to accelerate clinical trial execution, while always maintaining the human in the loop.
Key use cases for AI in clinical development
Study design and planning
-
Study design optimization
-
Precise site selection
-
Patient identification
Study start-up and execution
- Achieve increased speed and quality of statistical programming
- Site contracting, grant management and payment solutions
- Monitoring visit preparation and report generation
Clinical trial data and analysis
- SDTM conversion and automated data workflows optimized with AI
Regulatory and safety
- Accelerate speed of delivery in medical writing
- Improve efficiency and effectiveness of regulatory affairs functions via machine learning and generative AI tools
- Streamline adverse event case processing for speed and higher quality
Post approval activities
- Enhance evidence generation for market access and HEOR strategy with predictive modeling tools
Operational efficiency with AI-driven automation
Nearly 50 robotic process automation (RPA – aka bots) solutions have been deployed in workflows across Parexel. These bots drive efficiency, enable faster timelines, and deliver first time quality.
The vision behind our AI-enabled platform
Meaningful change always starts with a vision. We envisioned an AI-enabled platform that automates data management processes end to end—from data input, through analysis, to regulatory submission.
Partnering with Palantir to build an AI ecosystem
Today we’re building the end-to-end AI ecosystem with Palantir Technologies Inc, a software company that builds platforms to power real-time, AI-driven decision-making.
Transforming trial execution with AI-powered workflows
Palantir’s core product, AIP, is used to create a central operating system with tools that support AI automation combined with human-in-the-loop decision making. Parexel is leveraging AIP to transform trial execution from siloed, semi-manual tasks into integrated, AI-powered workflows driven by scalable insights and predictive intelligence.
“Data standardization is the foundation for unlocking the value of AI in clinical research. We believe the combination of Palantir’s AIP platform and Parexel’s vision for clinical trial transformation will set new benchmarks for speed, accuracy and first-time quality.”
-Dan Ballard, Senior Vice President, Digital Enablement and Innovation
Ethically leveraging AI in clinical trials
The six principles set out below describe how Parexel conceives, develops, deploys, and monitors AI applications intended for use in clinical development and throughout our business. By adhering to these tenets, we ensure that Parexel respects the rights of all relevant stakeholders, mitigates or eliminates known risks, and uses AI applications safely.
- Thoughtful design and deployment
- Accountability and senior-level governance
- Human oversight and control
- Transparent AI
- Regulatory conformance and legal compliance
- Security and privacy
Learn more about Parexel’s principles for artificial intelligence and how we are applying them to build an AI roadmap with solutions that are conceived, developed, and deployed responsibly.
Our journey with AI and HyperAutomation is just beginning. We look forward to sharing how we’re using AI to help manage the increasing complexity of clinical development, including opportunities to expedite development timelines so life-changing products reach patients quicker.
Our Experts
Stephen Pyke, DIC
Chief Clinical Data & Digital Officer
Jonathan Shough
Chief Information Officer
Evan Lin
Global Head AI Labs
Thomas Pietsch
Global Head of Scientific Data Technology and AI
Jeff Kopicko
Vice President, Data Operations
Martin Keywood
Scientific Data Technology Senior Director
Paul Isherwood
Senior Director, Patient Strategy & Insights
Jackie Vanderpuye-Orgle, Ph.D.
Vice President, and Global Head of Advanced Analytics, RWE & HEOR
Katie Connelly
Senior Vice President, Global Head of Regulatory Affairs
Our Experts
Our latest insights
Blog
AI Milestones: AI-enabled EKG reads and alerts save lives: human-AI collaboration in practice
Jun 6, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Article
Delivering AI-managed clinical research data: Parexel’s end-to-end automation strategy
Mar 11, 2025
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024
Podcast
Enabling Successful Sites: Episode 4, Part Two: Leveraging AI to improve patient recruitment and retention
Jan 6, 2025
Blog
Putting AI to work in your safety program
May 21, 2021
Blog
Generative AI and how we can harness its power in clinical development
Sep 26, 2023
Our latest insights
Blog
AI Milestones: AI-enabled EKG reads and alerts save lives: human-AI collaboration in practice
Jun 6, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Article
Delivering AI-managed clinical research data: Parexel’s end-to-end automation strategy
Mar 11, 2025
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024
Podcast
Enabling Successful Sites: Episode 4, Part Two: Leveraging AI to improve patient recruitment and retention
Jan 6, 2025
Frequently asked questions
Artificial Intelligence (AI) is increasingly being applied to various aspects of clinical development, revolutionizing the way clinical trials are designed, conducted, and analyzed. One of the primary applications of AI in this field is in patient recruitment and retention. AI algorithms can analyze vast amounts of patient data, including electronic health records, genetic information, and even social media data, to identify potential candidates who meet specific trial criteria. This not only speeds up the recruitment process but also helps in finding more diverse and representative patient populations. Additionally, AI is being used to optimize trial designs by predicting potential outcomes, identifying optimal dosing regimens, and suggesting the most effective endpoints for a study.
Another significant area where AI is making an impact is in data analysis and management. Machine learning algorithms can process and analyze large volumes of clinical trial data much faster and more accurately than traditional methods. This includes identifying patterns and trends that might be missed by human analysts, detecting potential safety signals earlier, and providing real-time insights during the trial. AI is also being employed in image analysis for radiology and pathology, automating the interpretation of medical images and potentially reducing human error. Furthermore, natural language processing (NLP) techniques are being used to extract valuable information from unstructured data sources such as medical literature, patient reports, and clinical notes, enhancing the overall understanding of diseases and treatment efficacy.
The use of Artificial Intelligence (AI) in clinical research offers numerous benefits that can significantly enhance the efficiency, accuracy, and overall quality of clinical trials. One of the primary advantages is the acceleration of the research process. AI can rapidly analyze vast amounts of data, including medical literature, patient records, and trial results, to identify patterns and insights that might take human researchers much longer to discover. This speed can lead to faster drug development timelines and quicker identification of potential treatments. AI also improves patient recruitment and retention by more accurately matching patients to suitable trials based on their specific characteristics and medical histories. This not only speeds up the recruitment process but also helps in creating more diverse and representative study populations, potentially leading to more generalizable results.
Another significant benefit is the enhancement of data quality and analysis. AI algorithms can detect anomalies, inconsistencies, and potential errors in data collection and entry, improving the overall integrity of clinical trial data. Machine learning models can predict patient outcomes, identify potential safety issues earlier, and even suggest modifications to trial designs in real-time, potentially saving resources and improving patient safety. AI can also assist in the analysis of complex datasets, including genomic data and medical imaging, providing deeper insights into disease mechanisms and treatment efficacy. Furthermore, AI-powered tools can automate many time-consuming tasks, such as literature reviews and regulatory document preparation, allowing researchers to focus on more critical aspects of their work. This automation not only saves time but also reduces the potential for human error, leading to more reliable and reproducible research outcomes.
AI significantly improves patient recruitment for clinical trials through several innovative approaches. Firstly, AI algorithms can rapidly analyze vast amounts of data from various sources, including electronic health records (EHRs), claims data, genomic databases, and even social media, to identify potential trial participants who meet specific inclusion and exclusion criteria. This process, known as patient matching, is much faster and more accurate than traditional manual screening methods. AI can consider complex combinations of factors such as medical history, current medications, genetic markers, and lifestyle factors to find the most suitable candidates. This not only speeds up the recruitment process but also helps in identifying patients who might have been overlooked by conventional methods, potentially leading to more diverse and representative study populations.
Moreover, AI enhances the efficiency and personalization of the recruitment process. Machine learning models can predict which patients are most likely to enroll and remain in a trial, allowing researchers to focus their recruitment efforts more effectively. AI-powered chatbots and virtual assistants can provide potential participants with 24/7 access to trial information, answer questions, and even assist with initial screening processes. These tools can communicate in multiple languages and adapt their interaction style based on user preferences, making the recruitment process more accessible and patient-friendly. Additionally, AI can analyze patterns in successful recruitments and dropouts, providing insights to optimize recruitment strategies and improve retention rates. By streamlining these processes, AI not only accelerates trial timelines but also potentially reduces costs associated with recruitment delays and patient dropouts.
AI can significantly enhance both the speed and quality of clinical development through various innovative applications. In terms of speed, AI algorithms can rapidly analyze vast amounts of data from multiple sources, including scientific literature, clinical trial databases, and patient records, to identify potential drug candidates and optimal trial designs. AI can also accelerate patient recruitment by quickly identifying suitable candidates from electronic health records and other data sources, matching them to appropriate trials based on complex criteria. During the trial itself, AI-powered real-time data analysis can provide immediate insights into trial progress, allowing for quick adjustments to improve efficiency. Moreover, AI can automate many time-consuming tasks such as data entry, validation, and preliminary analysis, freeing up researchers to focus on more complex aspects of the study.
In terms of quality, AI contributes to clinical development in several ways. Machine learning algorithms can improve the accuracy of patient selection, ensuring that trials include the most appropriate participants, which can lead to more reliable and generalizable results. AI can enhance data quality by detecting anomalies, inconsistencies, or potential errors in data collection and entry, reducing the risk of flawed analyses. Advanced AI models can predict potential safety issues or treatment efficacy earlier in the trial process, allowing for timely interventions or adjustments. AI can also assist in more sophisticated data analysis, uncovering subtle patterns or relationships in complex datasets that might be missed by traditional statistical methods. Furthermore, AI-powered natural language processing can extract valuable insights from unstructured data sources like medical literature and patient reports, enriching the overall understanding of the treatment under study. By improving both speed and quality, AI has the potential to make clinical development more efficient, cost-effective, and ultimately more successful in bringing new treatments to patients.